Clinical Trials Logo
  1. Home
  2. Coronavirus
  3. NCT04373148
  4. Details
NCT04373148 Clinical Trial

Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19

Coronavirus Clinical Trial

Official title:
Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04373148
Other study ID # IRB-55689
Secondary ID 2U19AI0572291U54
Status Completed
Phase
First received
Last updated
Start date April 8, 2020
Est. completion date May 31, 2022

Study information
Verified date June 2022
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to test over time immunity to SARS-CoV-2, a recently identified coronavirus responsible for the 2019 world-wide pneumonia outbreak known as COVID-19. Adults and children diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Recruitment information / eligibility
Status Completed
Enrollment 316
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Adults (18 years and older) and children with confirmed COVID-19 (RT-PCR diagnosis). - Adults (18 years and older) and children without COVID-19 for controls (who test negative for COVID-19 but may have viral symptoms) Exclusion Criteria: - Patients with special risks attendant to venipuncture will be excluded.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• There is no intervention
There is no intervention

Locations
Country Name City State
United States Stanford Health Care - ValleyCare Pleasanton California
United States Stanford University, Hospital, and Clinics Stanford California

Sponsors (4)
Lead Sponsor Collaborator
Stanford University National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Testing Immunity to SARS-CoV-2 over time 1 year
Secondary Testing the virus over time 1 year
See also
  Status Clinical Trial Phase
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT05359770 - Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19 N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Not yet recruiting NCT06025812 - Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) N/A
Recruiting NCT05289115 - Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS N/A
Completed NCT04779138 - Increasing Vaccine Uptake in Underresourced Public Housing Areas N/A
Completed NCT04953078 - A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Phase 1
Not yet recruiting NCT05868239 - Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study N/A
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A
Completed NCT04818164 - Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04572399 - UVA Light Device to Treat COVID-19 N/A
Recruiting NCT04610567 - Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Phase 1/Phase 2
Recruiting NCT04772170 - Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Recruiting NCT04581954 - Inflammatory Signal Inhibitors for COVID-19 (MATIS) Phase 1/Phase 2
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Completed NCT05572840 - Wear Your Mask, Wash Your Hands, Don't Get COVID-19 N/A
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3